Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

US11618790B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Michael Gerg · Munich, DE
• Dieter Heindl · Munich, DE
• Gerhard Niederfellner · Oberhausen, DE
• Wolfgang Schaefer · Sankt Augustin, DE
• Michael Schraeml · Penzberg, DE
• Michael Tacke · Munich, DE

Key dates

• Filing date: Dec 5, 2019
• Grant date: Apr 4, 2023
• Expiry date: Feb 9, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.